NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM).

被引：0
|
作者：
Galanis, E
Buckner, JC
Maurer, M
Ballman, K
Hidalgo, M
Kreisberg, JI
Boni, J
James, CDD
Jenkins, RB
Walsh, DJ
机构：
[1] Mayo Clin, Coll Med, Rochester, MN USA
[2] Johns Hopkins Univ, Baltimore, MD USA
[3] UTHSCSA, San Antonio, TX USA
[4] N Cent Canc Treatment Grp, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1503
引用
收藏
页码：107S / 107S
页数：1
相关论文
共 50 条
  • [21] A PHASE II TRIAL OF SUNITINIB IN THE TREATMENT OF RECURRENT GLIOBLASTOMA (GBM)
    Kreisl, Teri N.
    Smith, P.
    Iwamoto, Fabio
    Sul, Joohee
    Butman, John A.
    Fine, Howard A.
    NEURO-ONCOLOGY, 2010, 12 : 71 - 72
  • [22] Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma
    Ghobrial, Irene M.
    Vij, Ravi
    Munshi, Nikhil C.
    Schlossman, Robert L.
    Laubach, Jacob
    Campagnaro, Erica L.
    Leduc, Renee
    Rourke, Meghan
    Chuma, Stacey
    Kunsman, Janet
    Dollard, Akari M.
    Warren, Diane
    Harris, Brianna
    Sam, Amy
    Anderson, Kenneth C.
    Richardson, Paul
    BLOOD, 2009, 114 (22) : 311 - 312
  • [23] Phase I Trial of CCI-779 and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma
    Roccaro, A. M.
    Leduc, R.
    Nelson, M.
    Sam, A.
    Chuma, S.
    Colson, K.
    O'Connor, K.
    Ghobrial, I. M.
    Munshi, N. C.
    Schlossman, R.
    Harris, B.
    Warren, D.
    Dollard, A. M.
    Laubach, J.
    Vij, R.
    Campagnaro, E.
    Birner, A.
    Dixon-Lipscomb, V.
    Anderson, K. C.
    Richardson, P. G.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S86 - S86
  • [24] A PHASE II TRIAL OF EVEROLIMUS IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME
    Cloughesy, Timothy
    Raizer, J.
    Drappatz, J.
    Gerena-Lewis, M.
    Rogerio, J.
    Yacoub, S.
    Desjardin, A.
    NEURO-ONCOLOGY, 2011, 13 : 42 - 43
  • [25] A PHASE II TRIAL OF VANDETANIB FOR PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME
    Kreisl, Teri
    Burman, John A.
    Albert, Paul
    Kim, Lyndon
    Moore, Kraig
    Fine, Howard
    NEURO-ONCOLOGY, 2008, 10 (05) : 827 - 827
  • [26] Final results of a phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
    Witzig, T
    Geyer, S
    Ghobrial, I
    Inwards, D
    Fonseca, R
    Kurtin, P
    Ansell, S
    Kaufmann, S
    ANNALS OF ONCOLOGY, 2005, 16 : 65 - 65
  • [27] Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioblastoma multiforme (GBM).
    Shih, Kent C.
    Patel, Manish R.
    Butowski, Nicholas A.
    Bacha, Jeffrey A.
    Brown, Dennis
    Garner, William J.
    Stelno, Anne
    Schwartz, Richard Stephen
    Kanekal, Sarath
    Lopez, Lorena
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] PHASE I/II STUDY OF DIANHYDROGALACTITOL IN PATIENTS WITH RECURRENT MALIGNANT GLIOBLASTOMA MULTIFORME (GBM)
    Shih, Kent
    Patel, Manish
    Butowski, Nicholas
    Bacha, Jeffrey
    Brown, Dennis
    Garner, William
    Steino, Anne
    Schwartz, Richard
    Kanekal, Sarath
    Lopez, Lorena
    Burris, Howard A., III
    NEURO-ONCOLOGY, 2014, 16
  • [29] Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results
    Merchan, J. R.
    Liu, G.
    Fitch, T.
    Picus, J.
    Qin, R.
    Pitot, H. C.
    Maples, W.
    Erlichman, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] Phase II trial of temsirolimus (CCI-779) in patients with relapsed or refractory multiple myeloma (MM): Preliminary results.
    Farag, S. S.
    Zhang, S.
    Miller, M.
    Buckner, M.
    Kraut, E.
    Chan, K.
    Eng, C.
    Byrd, J. C.
    Dancey, J. E.
    Grever, M. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 450S - 450S
12345